Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

L-Glutamine and Reduced Oral Mucositis Severity

Research synthesisModerate evidenceSmall effect5 studies · 3 beneficial · 2 neutral · 0 harmful

Across 5 studies, 3 reported beneficial effects (one moderate, two small) and 2 found neutral effects on reducing oral mucositis severity. Most evidence comes from clinical populations with cancer, particularly head and neck cancer patients undergoing radiotherapy or chemoradiotherapy. The median study duration was 49 days, and the most-studied dose was 5 g of L-glutamine (in one RCT), though dose information was limited across the included papers.

  • Effective dose range: 5 g daily (single trial)
  • Studied populations: patients with head and neck cancer undergoing radiotherapy, pediatric cancer patients receiving chemo-/radiotherapy, general cancer patients

Caveats: Available evidence is overwhelmingly positive (3 of 5 studies beneficial) — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 5 studies) — conclusions should be considered preliminary. Two neutral studies did not reach statistical significance, and one used NCI scale which showed no difference.

Generated May 13, 2026
Doses used in studies
  • g/day: 5 (median 5, IQR 55) 1 study
Time to effect
Median: 7 weeks · IQR 7 weeks7 weeks · Range 7 weeks7 weeks — Reported in 1 of 5 studies
Safety in these studies
5 of 5 papers
Back to top